Barclays Private Equity sells GHD GesundHeits GmbH Deutschland to IK Investment Partners

Barclays Private Equity sells GHD GesundHeits GmbH Deutschland (“GHD” or the “Company”) to IK Investment Partners.

 

• ​Execution of a successful buy & build strategy since investment in 2007, including four acquisitions
• GHD is now Germany’s largest out-patient health, treatment and service provider
• Management remains involved in Company
• IK Investment Partners is the ideal partner for further corporate development

With the support of Barclays Private Equity, GHD has successfully implemented a buy & build strategy, increasing the Company’s turnover almost five-fold since 2006. The consideration for the transaction is undisclosed.

In August 2007, Barclays Private Equity acquired a majority holding in GHD– located in Ahrensburg, near Hamburg – and since then has successfully increased its holding through the Company’s buy & build strategy.  Strategic acquisitions in stoma care product manufacturer For Life – specialists for individual infusion solutions (since 2010: Profusio GesundHeits GmbH Deutschland) - and in two logistics providers Sangro and DVG, have reinforced the Company in the strategic growth fields of oncology and logistics, and permanently established GHD as Germany’s largest out-patient health, treatment and service provider.

In 2010, GHD will achieve, with over 1,500 employees, a turnover of approximately €300 million: a five-fold increase compared with 2006.  Andreas Rudolph, the founder and managing director of the GHD Group, will remain with the Company.

"We are glad of the opportunity to thank the Management team supporting Andreas Rudolph for this excellent performance. The impressive corporate development of the GHD Group is an excellent example of organic, sustainable growth, successful development and the expansion of a medium-level player to the status of market leader thanks to stable investment from proprietary capital and sound management", commented Dirk Schekerka, managing director of Barclays Private Equity.

Schekerka continued: "In conjunction with the Management of GHD, we are convinced that - in IK Investment Partners - we have found a powerful and stable partner for the continued expansion of the GHD Group".

Andreas Rudolph founded the company in 1992, launching an innovative home care service on the German health market: ambulatory provision of medical aid and medicine services for patients in their home environment. In 1998, Coloplast, the Danish adjuvant manufacturer, joined Andreas Rudolph’s venture in order to finance growth and develop new projects. The move enabled the company to diversify the therapy portfolio and offer, alongside stoma and incontinence care products, enteral and parenteral nutrition, as well as further intravenous therapies.   In 2005, a joint venture with HAD Apotheke Deutschland successfully became the foundation for supporting customers with pharmaceutical supplies, in particular with prescription medicines.

Now, with more than 1,500 employees, these divisions operate under the joint umbrella of GHD GesundHeits GmbH Deutschland and provide services to approximately 3,000 customers catering for out-patients and bed patients: approximately 70,000 patients in total.

Dirk Schekerka and Oskar Schilcher led the deal for Barclays Private Equity.